Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Consistency of Immunohistochemical Detecting Assays Using E1L3N and 22C3 Monoclonal Antibodies for Detection of PD-L1 Expression in NSCLC Patients: A Prospective CONFIDENCE Study

NCT05129462 is registered in ClinicalTrials.gov with Hunan Province Tumor Hospital as lead sponsor.

NCT NCT05129462
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05129462 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Consistency of Immunohistochemical Detecting Assays Using E1L3N and 22C3 Monoclonal Antibodies for Detection of PD-L1 Expression in NSCLC Patients: A Prospective CONFIDENCE Study
Lead sponsor
Hunan Province Tumor Hospital
Phase
Observational
Overall status
Completed
Start date
August 5, 2018
Completion date
October 1, 2021
Enrollment
52 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non small cell lung cancer